Skip Navigation

JNCI Journal of the National Cancer Institute 2001 93(6):413-414; doi:10.1093/jnci/93.6.413
© 2001 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Gazdar, A. F.
Right arrow Articles by Czerniak, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gazdar, A. F.
Right arrow Articles by Czerniak, B.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 93, No. 6, 413-414, March 21, 2001
© 2001 Oxford University Press

EDITORIAL

Filling the Void: Urinary Markers for Bladder Cancer Risk and Diagnosis

Adi F. Gazdar, Bogdan Czerniak

Affiliations of authors: A. F. Gazdar, The Hamon Center for Therapeutic Oncology Research and Department of Pathology, The University of Texas Southwestern Medical Center, Dallas; B. Czerniak, Department of Pathology, The University of Texas M. D. Anderson Cancer Center, Houston.

Correspondence to: Adi F. Gazdar, M.D., The Hamon Center for Therapeutic Oncology Research, 6000 Harry Hines Blvd., Dallas, TX 75390–8593 (e-mail: gazdar@simmons.swmed.edu).

Because most advanced invasive or metastatic cancers have low cure rates, risk assessment and early detection of the clinically occult premalignant phases of neoplasia are of particular importance. The National Cancer Institute (Bethesda, MD) has recently implemented an innovative new program, the Early Detection Research Network (its website is http://cancer.gov.edrn), where clinicians and scientists collaborate closely to develop and validate new markers and technologies for achieving these goals.

For studies of risk assessment and early detection, carcinomas arising in the urinary bladder are as close to ideal as any of the cancers arising in the internal organs. Urinary bladders are highly accessible and can be monitored by a variety of noninvasive or minimally invasive techniques. The entire mucosal surface at risk, the bladder urothelium, can be examined and biopsy specimens can be taken via a simple endoscopic procedure; moreover, exfoliated cells or secreted products can be examined repeatedly in . . . [Full Text of this Article]

NOTES

REFERENCES


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Proc. Natl. Acad. Sci. USAHome page
S. Lee, J. Jeong, T. Majewski, S. E. Scherer, M.-S. Kim, T. Tuziak, K. S. Tang, K. Baggerly, H. B. Grossman, J.-H. Zhou, et al.
Forerunner genes contiguous to RB1 contribute to the development of in situ neoplasia
PNAS, August 21, 2007; 104(34): 13732 - 13737.
[Abstract] [Full Text] [PDF]